Natera (NASDAQ: NTRA) has announced successful results from the Phase III CALGB/SWOG 80702 clinical trial for colorectal cancer (CRC) treatment. The trial, involving approximately 1,000 patients, demonstrated that Signatera-positive patients treated with a combination of chemotherapy and celecoxib showed a 40% improvement in overall survival compared to those treated with chemotherapy alone.
Key findings include:
- The addition of celecoxib to chemotherapy significantly improved disease-free survival (DFS) in Signatera-positive patients, with a three-year DFS of 44.1% versus 26.6%.
- Signatera was confirmed as a powerful tool for predicting cancer recurrence.
Additionally, the ALTAIR clinical trial, which studied 243 Signatera-positive patients, showed promising results for stage IV CRC patients treated with Trifluridine/Tipiracil (FTD/TPI): These patients demonstrated a median DFS of 9.76 months compared to 3.96 months in the placebo group.
Signatera enables personalized treatment by identifying patients who will benefit most from additional therapy. Adding celecoxib to chemotherapy reduces the risk of recurrence and improves patient survival. These results could lead to the development of new standards in colorectal cancer treatment.
Natera continues to explore the use of Signatera in treating other cancers, aiming to make it an integral part of personalized medicine.